000 02758cam a2200349 a 4500
003 EG-GiCUC
005 20250223032427.0
008 191028s2019 ua dh f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.19.04.Ph.D.2019.Ah.E
100 0 _aAhmed Elsayed Elbadawy Saleh
245 1 0 _aEvaluation of locoregional control and survival after total mesorectal excision for middle and lower rectal cancer /
_cAhmed Elsayed Elbadawy Saleh ; Supervised Faisal Abdelmenem Amer , Hussien Osama Soliman , Alaadin Hussien Ahmed
246 1 5 _aتقييم معدل التحكم الموضعي و معدل البقاء بعد الأستئصال الجذري و تشريح الغدد اليمفاوية للمنطقة الوسطى والدنيا لسرطان المستقيم
260 _aCairo :
_bAhmed Elsayed Elbadawy Saleh ,
_c2019
300 _a182 P. :
_bcharts , facsimiles ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology (Surgical)
520 _aIntroduction: Colorectal cancer is the second- and third-most common cancer in women and men, respectively. In 2012, 614,000 women (9.2% of all new cancer cases) and 746,000 men (10.0% of new cancer cases) were diagnosed with colorectal cancer worldwide. Combined, in both sexes, colorectal cancer is the third-most common cancer and accounts for 9.7% of all cancers excluding non-melanoma skin cancer. There are four major goals in the treatment of a patient with rectal cancer: (1) local control; (2) long-term survival; (3) preservation of anal sphincter, bladder, and sexual function; and (4) maintenance or improvement in quality of life. These goals are best achieved through a multi-modality approach delivered by a multi-disciplinary team. The mainstay of treatment for patients with rectal cancer has been curative surgical resection. Significant improvements in local control and survival have been seen with the implementation of total mesorectal excision (TME) and the addition of neoadjuvant chemoradiotherapy (CRT). AIM OF THE WORK The aim of this study is the evaluation of locoregional control for middle and lower rectal cancer & their impacts on the survival after total mesorectal excision at National Cancer Institute Cairo University
530 _aIssued also as CD
653 4 _aNeoadjuvant
653 4 _aRectal cancer
653 4 _aTME
700 0 _aAlaadin Hussien Ahmed ,
_eSupervisor
700 0 _aFaisal Abdelmenem Amer ,
_eSupervisor
700 0 _aHussien Osama Soliman ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aAsmaa
_eCataloger
905 _aNazla
_eRevisor
942 _2ddc
_cTH
999 _c74827
_d74827